Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate updates, shifting payor mixes and physician joint-venture agreements turn every Surgery Partners disclosure into a maze of acronyms and footnotes. If you have ever searched through a 300-page document just to learn which facilities drove same-store growth, you know the challenge. Stock Titan brings clarity by pairing each release with AI-powered summaries that translate reimbursement tables and regulatory language into plain English.
You will find every filing here as soon as it hits EDGAR: the Surgery Partners annual report 10-K simplified for long-term trends, each Surgery Partners quarterly earnings report 10-Q filing broken down into case-volume and payor-mix drivers, and every Surgery Partners 8-K material events explained so you see why management moved quickly. Need trading intel? Our dashboard tracks Surgery Partners insider trading Form 4 transactions and delivers Surgery Partners Form 4 insider transactions real-time. For governance questions, the Surgery Partners proxy statement executive compensation section highlights how physician leaders are paid. All documents come with concise, AI-generated key points so you can start understanding Surgery Partners SEC documents with AI instead of parsing line items yourself.
Use these insights to compare segment margins across facilities, monitor Surgery Partners executive stock transactions Form 4 before earnings, and follow guidance revisions the moment they appear. Whether you are preparing a model, monitoring covenant compliance, or simply looking for Surgery Partners earnings report filing analysis, our platform saves hours and ensures nothing slips past you.
Surgery Partners, Inc. (SGRY) reported higher revenue and improved operating performance in Q3 2025. Revenue rose to $821.5 million from $770.4 million, driven by same‑facility growth and recent portfolio actions. Operating income increased to $105.7 million from $60.9 million as salaries, supplies, and professional fees scaled with volume. Net loss attributable to Surgery Partners narrowed to $22.7 million from $31.7 million as interest expense remained elevated at $74.9 million.
Management highlighted days‑adjusted same‑facility revenue up 6.3% year over year, with a 2.8% increase in revenue per case and a 3.4% lift in same‑facility cases. For the nine months, revenue reached $2,423.7 million versus $2,249.9 million, while the net loss attributable to the company was $62.9 million.
Liquidity and capital structure shifted following an August refinancing. The company entered into $1,383 million of 2025 Refinancing Term Loans maturing in 2030 at Term SOFR plus 2.50% (or an alternate base rate plus 1.50%) and extended revolving commitments to 2028. Cash and cash equivalents were $203.4 million, with $405.9 million of availability on the $703.8 million revolver. Total debt was $3,563.6 million, including $800.0 million of 7.250% senior notes due 2032. As of November 3, 2025, common shares outstanding were 129,341,779.
Surgery Partners, Inc. (SGRY) furnished an 8-K announcing results for the three and nine months ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing the period’s performance.
The disclosure under Item 2.02 is provided pursuant to General Instruction B.2 and is deemed furnished, not filed. The release includes non-GAAP financial measures with reconciliations to the most comparable GAAP measures.
Surgery Partners, Inc. (SGRY) submitted a Form 144 notifying a proposed sale of 3,145 common shares through UBS Financial Services with an approximate market value of 65,269.9, and an approximate sale date of
The filing also lists multiple prior open-market sales by the named person, Wayne DeVeydt, across dates from
Surgery Partners, Inc. (SGRY) Rule 144 notice shows an insider intends to sell 25,000 newly acquired common shares through UBS Financial Services on
The filing also lists multiple recent sales by Wayne DeVeydt totaling numerous transactions between
Surgery Partners, Inc. (SGRY) Form 144 notice reports a planned sale of 18,134 common shares through UBS on 09/29/2025 with an aggregate market value of $399,822. The filer states these shares were acquired the same day via an equity option exercise, and the proposed sale will be executed on NASDAQ. The filing lists extensive insider selling by Wayne DeVeydt over the prior three months totaling 719,604 shares sold across multiple dates, generating cumulative gross proceeds reported in the filing. The company has 128,209,410 shares outstanding, which provides context for the scale of these transactions relative to the float.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 5,627 common shares through UBS Financial Services on September 26, 2025. The shares were recorded as acquired the same day via equity compensation and an equity option exercise. The reported aggregate market value for the proposed sale is $123,794 and the issuer has 128,209,410 shares outstanding. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling 713,977 shares sold across dates from August 21, 2025 through September 23, 2025 with individual gross proceeds reported for each lot.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 25,000 common shares to be executed on 09/23/2025 through UBS Financial Services (Weehawken, NJ). The filing states these shares were acquired on 09/23/2025 as equity compensation through an equity option exercise from Surgery Partners, Inc. The notice is submitted under Rule 144 and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The filing also discloses numerous recent open-market sales by the same person, dated between 08/21/2025 and 09/22/2025, across multiple transactions.
Surgery Partners, Inc. (SGRY) Rule 144 notice discloses a proposed sale of 50,000 common shares through UBS Financial Services (Nasdaq) with an aggregate market value of $1,092,666 and an approximate sale date of 09/22/2025. The shares were acquired and paid for on 09/22/2025 via an equity option exercise from Surgery Partners, Inc. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling large share blocks between 08/21/2025 and 09/19/2025, including transactions of 100,000, 150,000, and other lots with combined gross proceeds in the multi-million dollar range. The filer affirms no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 notice reports an intended sale of 10,613 common shares through UBS Financial Services on NASDAQ with an aggregate market value of $234,547.30. The securities were acquired the same day as equity compensation via an equity option exercise. The filer reports numerous recent open-market sales by Wayne DeVeydt totaling multiple transactions between August and September 2025, including sales of 100,000 and 150,000 share lots. The filing affirms the seller does not possess undisclosed material adverse information. The reported number of shares outstanding is 128,209,410, providing context for the relative scale of the transactions.
Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Surgery Partners (SGRY)?
What is the market cap of Surgery Partners (SGRY)?
